The aforementioned phase 1b/2 trial investigating the effects of navtemadlin in Merkel cell carcinoma will also examine the effect of combining navtemadlin with avelumab in patients who were anti–PD-1/anti–PD-L1–naïve. Here, CD274 is linked to Merkel cell skin cancer.